There is actually 70 m savings in operating expenses , so Mayne is operating both Nexstellis and TXMD at profit for the first time , so they are correct 14 m +ve contribution and international segment always making profit , hopefully they add more dermatology products from similar companies to use the existing sales force . Smart idea
Mayne Pharma sees strong sales growth in FY 2023, page-70
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.38 |
Change
-0.100(2.23%) |
Mkt cap ! $372.6M | |||
| Open | High | Low | Value | Volume |
| $4.45 | $4.53 | $4.38 | $514.8K | 116.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4744 | $4.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.40 | 168 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| MYX (ASX) Chart |